NFL BIOSCIENCES : ANALYST COVER INITIATION BY INVEST SECURITIES
- Recommendation : PURCHASE
- Course objective: 4,90 €
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, today announces the initiation of analyst coverage of NFL Biosciences by Invest Securities, an independent financial services provider whose research activity is led by 12 professionals covering more than 120 companies in various sectors.
The coverage of NFL Biosciences follows the establishment of a research contract following its IPO on Euronext Growth Paris in June 2021. The analysis was carried out by Thibaut Voglimacci Stephanopoli, analyst specializing in securities Health and Medtech.
The analysis, available on the NFL Biosciences website (section ” Investors “), Recommends the NFL Biosciences share for purchase with a price target set at 4.90 euros.
Closing price prior to publication: € 3.59
About NFL Biosciences
NFL Biosciences is a Montpellier-based biopharmaceutical company whose most advanced botanical drug candidate is a smoking cessation aid. Called NFL-101, this natural product, extracted from standardized tobacco leaves and devoid of nicotine, is protected by two families of patents. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, long-term effective, short and personalized alternative.
Beyond NFL-101, NFL Biosciences has plans to develop botanical drugs for the treatment of cannabis use disorders and alcoholism.
More information on www.nflbiosciences.com
The actions NFL Biosciences are listed on Euronext Growth Paris. (FR0014003XT0 – ALNFL)
Bruno Lafont – email@example.com – 04 11 93 76 67
Calyptus Agency – firstname.lastname@example.org – 01 53 65 68 68